Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - atazanavir sulfate -

Канада - англійська - Health Canada

jamp pharma corporation - atazanavir (atazanavir sulfate) - capsule - 200mg - atazanavir (atazanavir sulfate) 200mg - hiv protease inhibitors

Канада - англійська - Health Canada

jamp pharma corporation - atazanavir (atazanavir sulfate) - capsule - 300mg - atazanavir (atazanavir sulfate) 300mg - hiv protease inhibitors

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 341.7 mg (equivalent: atazanavir, qty 300 mg) - capsule - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; purified water; hydrophobic colloidal silica anhydrous; magnesium stearate; titanium dioxide; indigo carmine; iron oxide red; gelatin; iron oxide black; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 341.7 mg (equivalent: atazanavir, qty 300 mg) - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; lactose monohydrate; sodium starch glycollate type a; purified water; magnesium stearate; titanium dioxide; indigo carmine; iron oxide red; gelatin; iron oxide black; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

США - англійська - NLM (National Library of Medicine)

a-s medication solutions - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 300 mg - reyataz® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: reyataz is contraindicated: table 6 displays drugs that are contraindicated with reyataz. drug class drugs within class that are contraindicated with reyataz clinical comment alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if reyataz is coadministered with ritonavir. pimozide potential for serious and/or life-threatening reactions such

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 341.71 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 341.71 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 227.81 mg (equivalent: atazanavir, qty 200 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - atazanavir sulfate, quantity: 227.81 mg (equivalent: atazanavir, qty 200 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).